Likewise, and similar to our findings, in 211 interferon-beta treated patients with CIS enrolled in the SET study, EBNA-1 and VCA antibodies were not associated with conversion to CDMS over two years. The gene discussed is IFNB1; the disease is in situ carcinoma.